16 October 2020 - EMA has recommended granting a conditional marketing authorisation in the European Union for Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of adult patients with mantle cell lymphoma when the symptoms or the disease come back or when they are not responding after two or more lines of systemic therapy.

Tecartus is the third CAR-T cell medicine to be recommended for approval in the EU. CAR-Ts are advanced therapies for cancer, they belong to a new generation of personalised cancer immunotherapies that are based on collecting and modifying patients’ own immune cells to treat their cancer.

Read EMA press release